<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966223</url>
  </required_header>
  <id_info>
    <org_study_id>RADY-BTG-TANN-HIDA/0603</org_study_id>
    <nct_id>NCT02966223</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver</brief_title>
  <official_title>A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary question of interest is quantifying the relationship between Y-90 liver therapy&#xD;
      and liver damage. Little is known on this subject. Present assumptions and calculations of&#xD;
      Y-90 administration are based on surgical lobar hepatectomies and external radiation beam&#xD;
      therapies. The investigators hope that by using a functional model of the liver, the&#xD;
      investigators can improve this important knowledge gap.&#xD;
&#xD;
      The investigators will be enrolling patients planning to receive Y-90 therapy for the&#xD;
      treatment of liver malignancies. The diagnosis of a primary liver cancer, hepatocellular&#xD;
      carcinoma (HCC), is usually made by a combination of specific imaging findings and clinical&#xD;
      criteria; only rarely is a confirmatory biopsy performed. This is due to the high accuracy of&#xD;
      the present diagnostic model and the significant risk of biopsy and tumor seeding.&#xD;
&#xD;
      Y-90 therapy involves administering radioactive particles to liver tumors by placing a&#xD;
      catheter in a hepatic artery supplying the tumor using angiographic techniques and injection&#xD;
      of these particles.&#xD;
&#xD;
      Y-90 Positron Emission Tomography-Computed Tomography (PET/CT) imaging has been established&#xD;
      as a method to validate and quantitate distribution of Yttrium after Y-90 administration. The&#xD;
      post Y-90 therapy PET/CT images provide an imaging distribution of the Y-90, which is&#xD;
      essential for validation of administered versus planned dose to the liver lesion and&#xD;
      background liver.&#xD;
&#xD;
      If the investigators can compare the Y-90 distribution to estimate background liver radiation&#xD;
      distribution and dose (generated by the Y-90 PET/CT scan) combined with the global and&#xD;
      regional function map (generated by the hepatobiliary [HIDA] scan performed before and after&#xD;
      therapy), then the investigators will be assuming that the difference pre and post therapy in&#xD;
      global and regional function can be ascribed to the Y-90 administration. The investigators&#xD;
      will also analyze the Magnetic Resonance Imaging (MRI) and CT sets performed before and after&#xD;
      therapy and correlate the imaging results collected with clinical findings such as&#xD;
      ascites/encephalopathy and routine serological markers (bilirubin, albumin, International&#xD;
      normalized ratio [INR], etc.). With this information, the investigators will have the&#xD;
      potential to establish whether there is a relationship between Y-90 distribution to&#xD;
      non-tumoral (normal) hepatic parenchyma and the incidence and severity of&#xD;
      Radioembolization-Induced Liver Disease (REILD). This would have the potential to improve&#xD;
      selection criteria and outcomes in populations selected for Y-90 therapy in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Little is known on the potential relationship between Y-90 liver therapy and liver damage&#xD;
      this subject. Present assumptions and calculations of Y-90 administration are based on&#xD;
      surgical lobar hepatectomies and external radiation beam therapies.&#xD;
&#xD;
      As most participants that need Y90 based liver therapies have compromised livers, the&#xD;
      importance of knowing what potential collateral liver damage could be induced by Y90 is key&#xD;
      so as not induce liver failure. Successful treatment of a liver malignancy would not be&#xD;
      important if the potential mortality/morbidity risk of the treatment is higher or equal to&#xD;
      the existing malignancy.&#xD;
&#xD;
      As apposed to anatomical imaging looking for changes in size/shape which are late changes,&#xD;
      the investigators hope that by using a functional model of the liver, which can show early&#xD;
      changes of liver damage, the investigators can improve the sensitivity for detection of liver&#xD;
      damage and bridge this important knowledge gap. Additionally due to compensatory hypertrophy&#xD;
      of the non treated liver, potential liver damage estimated by lab tests may be masked, again&#xD;
      this emphasizes the importance of the measurement of the functional approach before and after&#xD;
      therapy.&#xD;
&#xD;
      The investigators will be enrolling participants planning to receive Y-90 therapy for the&#xD;
      treatment of liver malignancies. The diagnosis of a primary liver cancer, hepatocellular&#xD;
      carcinoma (HCC), is usually made by a combination of specific imaging findings and clinical&#xD;
      criteria; only rarely is a confirmatory biopsy performed. This is due to the high accuracy of&#xD;
      the present diagnostic model and the significant risk of biopsy and tumor seeding.&#xD;
&#xD;
      Y-90 therapy involves administering radioactive particles to liver tumors by placing a&#xD;
      catheter in a hepatic artery supplying the tumor using angiographic techniques and injection&#xD;
      of these particles.&#xD;
&#xD;
      Y-90 PET/CT imaging has been established as a method to validate and quantitate distribution&#xD;
      of Yttrium after Y-90 administration. The post Y-90 therapy PET/CT images provide an imaging&#xD;
      distribution of the Y-90, which is essential for validation of administered versus planned&#xD;
      dose to the liver lesion and background liver.&#xD;
&#xD;
      The investigators will be performing both specialized nuclear medicine HIDA and MRI scans&#xD;
      aimed at constructing a functional map of the liver before and 3 months after therapy.&#xD;
&#xD;
      The investigators will compare the Y-90 distribution to estimate background liver radiation&#xD;
      distribution and dose (generated by the Y-90 PET/CT scan) combined with the global and&#xD;
      regional function map (generated by the HIDA and MRI scans performed before and after&#xD;
      therapy), then the investigators will be assuming that the difference pre and post therapy in&#xD;
      global and regional function can be ascribed to the Y-90 administration.&#xD;
&#xD;
      The investigators will also analyze the MRI and NM data sets performed before and after&#xD;
      therapy and correlate the imaging results collected with clinical findings such as&#xD;
      ascites/encephalopathy and routine serological markers (bilirubin, albumin, INR, etc.).&#xD;
&#xD;
      With this information, the investigators will have the potential to establish whether there&#xD;
      is a relationship between Y-90 distribution to non-tumoral (normal) hepatic parenchyma and&#xD;
      the incidence and severity of REILD. This would have the potential to improve selection&#xD;
      criteria and outcomes in populations selected for Y-90 therapy in the future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor prematurely withdrew financial support.&#xD;
  </why_stopped>
  <start_date type="Actual">August 17, 2017</start_date>
  <completion_date type="Actual">April 24, 2020</completion_date>
  <primary_completion_date type="Actual">July 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary</measure>
    <time_frame>3 months</time_frame>
    <description>Difference in regional liver function between pre and 3 months post Yttrium 90 delivery using the HIDA functional imaging scans.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary</measure>
    <time_frame>3 months</time_frame>
    <description>Determine the difference in global liver function between pre and 3 months post Yttrium 90 delivery using the HIDA functional imaging scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary</measure>
    <time_frame>6 months</time_frame>
    <description>Correlation between the differences in liver function (both regional and global) with the Y 90 dose provided.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HCC</condition>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>MRI and HIDA scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRI and HIDA scan</intervention_name>
    <description>Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan</description>
    <arm_group_label>MRI and HIDA scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have the ability to understand and the willingness to sign a written&#xD;
             informed consent document.&#xD;
&#xD;
          2. Subjects must be â‰¥ 18 years of age at the time of signing informed consent.&#xD;
&#xD;
          3. Subjects must have a diagnosis of hepatocellular carcinoma (HCC) and a treatment plan&#xD;
             to undergo radioembolization therapy with Y-90 at Indiana University Health Hospital.&#xD;
&#xD;
          4. Subjects must be willing and able to comply with all procedures and visits required&#xD;
             for this protocol (pre-treatment, during treatment, and post-treatment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who have contraindications for receiving Y-90 therapy and any routine&#xD;
             procedures and imaging associated with Y-90 therapy, including subjects who are&#xD;
             pregnant or are planning to become pregnant, will not be eligible to participate in&#xD;
             this study. Female subjects who are of childbearing potential should inform her&#xD;
             treating physician should she become pregnant at any time during the course of the&#xD;
             study.&#xD;
&#xD;
          2. Subjects with contraindications for receiving hepatobiliary scans (HIDA scans) and&#xD;
             Magnetic Resonance Imaging (MRI scans) will not be eligible to participate in this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Tann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <results_first_submitted>June 5, 2020</results_first_submitted>
  <results_first_submitted_qc>September 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2020</results_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Mark Tann</investigator_full_name>
    <investigator_title>Associate Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02966223/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MRI and HIDA Scan</title>
          <description>MRI and HIDA scan: Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The trial was halted prematurely because sponsor withdrew funding. There is insufficient data to analyze. Inclusion criteria to participate in study being 18 years of age and older, Hepatocellular Carcinoma diagnoses and treatment plan to undergo radioembolization Y90 therapy, and not pregnant or planning to become pregnant during study.</population>
      <group_list>
        <group group_id="B1">
          <title>MRI and HIDA Scan</title>
          <description>MRI and HIDA scan: Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Average age of enrolled subjects is 66 years old.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Measure Description: Average age of enrolled population 66 years old. Average age of subjects who completed study 65 years old.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="8.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Gender of subjects that enrolled in study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Enrollment took place in Indianapolis, IN.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Enrollment</title>
          <description>Recruitment of volunteers who consented to participate in study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary</title>
        <description>Difference in regional liver function between pre and 3 months post Yttrium 90 delivery using the HIDA functional imaging scans.</description>
        <time_frame>3 months</time_frame>
        <population>The trial was halted prematurely because sponsor withdrew funding. There is insufficient data as funding to perform the analysis was withdrawn.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI and HIDA Scan</title>
            <description>MRI and HIDA scan: Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan</description>
          </group>
        </group_list>
        <measure>
          <title>Primary</title>
          <description>Difference in regional liver function between pre and 3 months post Yttrium 90 delivery using the HIDA functional imaging scans.</description>
          <population>The trial was halted prematurely because sponsor withdrew funding. There is insufficient data as funding to perform the analysis was withdrawn.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary</title>
        <description>Determine the difference in global liver function between pre and 3 months post Yttrium 90 delivery using the HIDA functional imaging scans.</description>
        <time_frame>3 months</time_frame>
        <population>The trial was halted prematurely because sponsor withdrew funding. There is insufficient funding for data to be analyzed properly.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI and HIDA Scan</title>
            <description>MRI and HIDA scan: Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary</title>
          <description>Determine the difference in global liver function between pre and 3 months post Yttrium 90 delivery using the HIDA functional imaging scans.</description>
          <population>The trial was halted prematurely because sponsor withdrew funding. There is insufficient funding for data to be analyzed properly.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary</title>
        <description>Correlation between the differences in liver function (both regional and global) with the Y 90 dose provided.</description>
        <time_frame>6 months</time_frame>
        <population>The trial was halted prematurely because sponsor withdrew funding. There is insufficient funding to properly analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>MRI and HIDA Scan</title>
            <description>MRI and HIDA scan: Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary</title>
          <description>Correlation between the differences in liver function (both regional and global) with the Y 90 dose provided.</description>
          <population>The trial was halted prematurely because sponsor withdrew funding. There is insufficient funding to properly analyze.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MRI and HIDA Scan</title>
          <description>MRI and HIDA scan: Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was halted prematurely because sponsor withdrew funding. There is insufficient data to analyze.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mark Tann, MD</name_or_title>
      <organization>Indiana University</organization>
      <phone>317- 948-8782</phone>
      <email>matann@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

